

Issued: March 16, 2020.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2020-05767 Filed 3-18-20; 8:45 am]

BILLING CODE 7020-02-P

## DEPARTMENT OF JUSTICE

### Bureau of Alcohol, Tobacco, Firearms and Explosives

[OMB Number 1140-0020]

#### Agency Information Collection Activities; Proposed eCollection eComments Requested; Firearms Transaction Record/Registro de Transacción de Armas de Fuego—ATF Form 4473 (5300.9)

**AGENCY:** Bureau of Alcohol, Tobacco, Firearms and Explosives, Department of Justice.

**ACTION:** 30-Day notice.

**SUMMARY:** The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), will submit the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed collection is being revised to include a Continuation Sheet, as well as changes to the content and layout of the form. There is also a decrease in the total respondents and burden hours associated with this information collection (IC). The proposed IC is also being published to obtain comments from the public and affected agencies.

**DATES:** The proposed information collection was previously published in the *Federal Register*, on December 26, 2019, allowing for a 60-day comment period. Comments are encouraged and will be accepted for an additional 30 days until April 20, 2020.

**FOR FURTHER INFORMATION CONTACT:** If you have additional comments, particularly with respect to the estimated public burden or associated response time, have suggestions, need a copy of the proposed information collection instrument with instructions, or desire any other additional information, please contact Helen Koppe, ATF Firearms & Explosives Industry Division either by mail at 99 New York Avenue NE, 6 N-652, Washington, DC 20226, by email at [FederalRegisterNoticeATFF4473@atf.gov](mailto:FederalRegisterNoticeATFF4473@atf.gov), or by telephone at 202-648-7173. Written comments and/or suggestions can also be directed to the Office of Management and Budget, Office of Information and Regulatory

Affairs, Attention Department of Justice Desk Officer, Washington, DC 20503 or sent to [OIRA\\_submissions@omb.eop.gov](mailto:OIRA_submissions@omb.eop.gov).

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

#### Overview of This Information Collection

(1) *Type of Information Collection:* Revision of a currently approved collection.

(2) *The Title of the Form/Collection:* Firearms Transaction Record/Registro de Transacción de Armas de Fuego.

(3) *The agency form number, if any, and the applicable component of the Department sponsoring the collection:* Form number: ATF Form 4473 (5300.9).

*Component:* Bureau of Alcohol, Tobacco, Firearms and Explosives, U.S. Department of Justice.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:*

*Primary:* Individuals or households.

*Other:* Business or other for-profit.

*Abstract:* The Firearms Transaction Record/Registro de Transacción de Armas de Fuego allows Federal firearms licensees to determine the eligibility of persons purchasing firearms. It also alerts buyers to certain restrictions on the receipt and possession of firearms.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* An estimated 17,189,101

respondents will utilize the form annually, and it will take each respondent 30 minutes to complete their responses.

(6) *An estimate of the total public burden (in hours) associated with the collection:* The estimated annual public burden associated with this collection is 8,594,551 hours, which is equal to 17,189,101 (# of respondents) \* 1 (# of responses per respondent) \* .5 (30 minutes).

(7) *An Explanation of the Change in Estimates:* The adjustments associated with this information collection include a reduction in the total respondents to this IC by 1,086,139. Consequently, the hourly burden for this IC has also decreased by 543,069 hours, since the last renewal in 2016.

If additional information is required contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE, 3E.405A, Washington, DC 20530.

Dated: March 13, 2020.

**Melody Braswell,**

*Department Clearance Officer for PRA, U.S. Department of Justice.*

[FR Doc. 2020-05676 Filed 3-18-20; 8:45 am]

BILLING CODE 4410-14-P

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-602]

#### Bulk Manufacturer of Controlled Substances Application: Navinta LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 18, 2020.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA **Federal Register** Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on September 23, 2019, Navinta LLC, 1499 Lower Ferry Road, Ewing, New Jersey 08618-1414 registered as a bulk manufacturer of the following basic class(es), of controlled substances:

Controlled substance	Drug code	Schedule
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....	8333	II
Levomethorphan .....	9210	II
Levorphanol .....	9220	II
Remifentanyl .....	9739	II
Fentanyl .....	9801	II

The company plans to bulk manufacture API quantities of the listed controlled substances for validation purposes and FDA approval.

Dated: March 5, 2020.

**William T. McDermott,**

*Assistant Administrator.*

[FR Doc. 2020-05750 Filed 3-18-20; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### John O. Dimowo, M.D.; Decision and Order

On August 28, 2017, the Drug Enforcement Administration (hereinafter, DEA) Administrative Law Judge Charles Wm. Dorman (hereinafter, ALJ), issued a Recommended Rulings, Findings of Fact, Conclusions of Law and Decision (hereinafter, RD) on the action to revoke the DEA Certification of Registration of John O. Dimowo, M.D. Neither party filed exceptions to the RD. Having reviewed and considered the entire administrative record before me, I adopt the ALJ's RD with minor modifications, where noted herein.\*<sup>A</sup>

Overall, with respect to this case, I appreciate Respondent's efforts to limit DEA time and resources by stipulating to many of the Government's fact allegations. However, as explained in the findings and conclusions below, his actions, including prescribing after a court's restriction and prescribing in Texas after his convictions and settlement in California without a DEA registration, contradicted the credibility of his words. The Respondent must convince the Administrator that his acceptance of responsibility and remorse are sufficiently credible to demonstrate that the misconduct will not recur. *Jeffrey Stein, M.D.*, 84 FR 46,968, 46,974 (2019). As described

herein, Respondent did not convince me or the ALJ that he could be entrusted with a DEA registration.

#### Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 824(a), I hereby revoke DEA Certificate of Registration BD3755571 issued to John O. Dimowo, M.D. Further, pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby deny any pending application of John O. Dimowo to renew or modify this registration, as well as any pending application of John O. Dimowo for registration in California. This Order is effective April 20, 2020.

Dated: March 2, 2020.

**Uttam Dhillon,**

*Acting Administrator.*

Paul E. Soeffing, Esq., for the

Government

Courtney E. Pilchman, Esq., for the

Respondent

#### Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision of the Administrative Law Judge

Charles Wm. Dorman, Administrative Law Judge. On July 21, 2016, the Drug Enforcement Administration ("DEA" or "Government") served John O. Dimowo, M.D., ("Respondent") with an Order to Show Cause ("OSC"), seeking to revoke his DEA Certificate of Registration ("COR"), Number BD3755571. Administrative Law Judge Exhibit ("ALJ-"), 1, 6. One of the allegations contained in the OSC was that the Respondent lacked state authority to handle controlled substances in California, where he was registered. In response to the OSC, the Respondent timely requested a hearing before an Administrative Law Judge. ALJ-2.

On September 2, 2016, the Government filed a Motion for Summary Disposition. ALJ-7. Therein, the Government argued that the Respondent lacked state authority in California to handle controlled substances, the state where the Respondent was registered with the DEA. ALJ-7, at 2. The Government stated that an Interim Suspension Order was issued against the Respondent by the Medical Board of California ("MBC") on June 10, 2016. ALJ-7, at 2-

3. Attached to the Government's Motion was a copy of the MBC's Interim Order of Suspension. ALJ-7, Ex. 1. The Government also stated that on June 28, 2016, a hearing was held before a California administrative law judge. ALJ-7, at 3. Following that hearing, on July 1, 2016, the state continued the suspension of the Respondent's medical license, and issued an Interim Order of Suspension. ALJ-7, Ex. 2.

On September 16,<sup>\*B</sup> 2016, the Respondent filed a Response to the Government Motion for Summary Disposition ("Response"). ALJ-8. Therein, the Respondent acknowledged that his California medical license had been suspended but asserted that he had "completed negotiation with the [MBC] to resolve the accusations that resulted in the temporary license suspension." ALJ-8, at 1. Attached to the Response was a copy of a Stipulated Settlement and Disciplinary Order between the Respondent and the Attorney General of California. ALJ-8, Ex. 1. In the Response, the Respondent requested that "the hearing on this matter be stayed pending the final approval of the negotiated settlement stipulation by the Executive Director of the [MBC]." ALJ-8,<sup>\*C</sup> at 1.

At that time, both parties agreed that the Respondent currently lacked state authority to handle controlled substances in California. Because there was no genuine question of fact, no adversarial hearing was required. *See, e.g., Jesus R. Juarez, M.D.*, 62 FR 14,945, 14,945 (1997). Therefore, because DEA precedent requires that a practitioner be authorized to handle controlled substances in the jurisdiction in which the practitioner is registered, I granted the Government's Motion for Summary Disposition on October 18, 2016. *See* ALJ-14. On November 15, 2016, I forwarded my October 18, 2016 Order Granting Summary Disposition and Recommended Rulings, Findings of Fact, Conclusions of Law, and Decision ("Recommended Decision") to the Acting Administrator of the DEA. ALJ-15.

Subsequent to the issuance of the Recommended Decision, the MBC restored a substantial portion of the

<sup>\*B</sup> Correction.

<sup>\*C</sup> Correction.

<sup>\*A</sup> I have made minor modifications to the RD. I have substituted initials or titles for the names of witnesses and patients to protect their privacy and I have made minor, nonsubstantive, grammatical changes. Where I have made substantive changes, omitted language for brevity or relevance, or where I have added to or modified the ALJ's opinion, I have noted the edits with an asterisk, and I have included specific descriptions of the modifications in brackets following the asterisk or in footnotes marked with an asterisk and a letter.